Name | Number of supported studies | Average coverage | |
---|---|---|---|
type II pneumocyte | 10 studies | 25% ± 8% |
Insufficient scRNA-seq data for expression of ALOX15B at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 93% | 8289.41 | 227 / 245 | 81% | 309.80 | 409 / 502 |
lung | 73% | 4451.08 | 423 / 578 | 61% | 39.58 | 702 / 1155 |
thymus | 46% | 332.55 | 299 / 653 | 70% | 48.34 | 426 / 605 |
breast | 66% | 2185.95 | 303 / 459 | 40% | 58.61 | 451 / 1118 |
skin | 83% | 2898.93 | 1495 / 1809 | 10% | 3.47 | 45 / 472 |
esophagus | 50% | 2024.86 | 729 / 1445 | 28% | 10.53 | 51 / 183 |
stomach | 67% | 443.52 | 239 / 359 | 6% | 0.78 | 18 / 286 |
spleen | 63% | 643.54 | 153 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 62% | 24.57 | 18 / 29 |
intestine | 47% | 311.81 | 457 / 966 | 8% | 2.21 | 43 / 527 |
adrenal gland | 51% | 246.27 | 131 / 258 | 3% | 0.49 | 7 / 230 |
bladder | 33% | 271.19 | 7 / 21 | 19% | 7.82 | 96 / 504 |
uterus | 23% | 151.43 | 39 / 170 | 27% | 10.06 | 126 / 459 |
pancreas | 7% | 36.22 | 24 / 328 | 35% | 7.28 | 63 / 178 |
tonsil | 0% | 0 | 0 / 0 | 42% | 12.71 | 19 / 45 |
adipose | 42% | 328.46 | 503 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 38% | 524.45 | 356 / 929 | 0% | 0 | 0 / 0 |
ovary | 16% | 75.08 | 28 / 180 | 19% | 2.65 | 82 / 430 |
kidney | 10% | 78.09 | 9 / 89 | 21% | 4.54 | 187 / 901 |
brain | 6% | 31.46 | 147 / 2642 | 23% | 4.86 | 162 / 705 |
blood vessel | 22% | 142.23 | 289 / 1335 | 0% | 0 | 0 / 0 |
liver | 4% | 24.79 | 8 / 226 | 7% | 4.39 | 28 / 406 |
heart | 8% | 39.57 | 73 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 5% | 0.47 | 4 / 80 |
muscle | 1% | 5.29 | 11 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0010744 | Biological process | positive regulation of macrophage derived foam cell differentiation |
GO_0032722 | Biological process | positive regulation of chemokine production |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0051122 | Biological process | hepoxilin biosynthetic process |
GO_0045786 | Biological process | negative regulation of cell cycle |
GO_0043651 | Biological process | linoleic acid metabolic process |
GO_2001303 | Biological process | lipoxin A4 biosynthetic process |
GO_0034440 | Biological process | lipid oxidation |
GO_0019372 | Biological process | lipoxygenase pathway |
GO_0035360 | Biological process | positive regulation of peroxisome proliferator activated receptor signaling pathway |
GO_0030850 | Biological process | prostate gland development |
GO_0071926 | Biological process | endocannabinoid signaling pathway |
GO_1901696 | Biological process | cannabinoid biosynthetic process |
GO_0006915 | Biological process | apoptotic process |
GO_0006644 | Biological process | phospholipid metabolic process |
GO_0030336 | Biological process | negative regulation of cell migration |
GO_0006629 | Biological process | lipid metabolic process |
GO_0019369 | Biological process | arachidonic acid metabolic process |
GO_0045926 | Biological process | negative regulation of growth |
GO_0045618 | Biological process | positive regulation of keratinocyte differentiation |
GO_0030856 | Biological process | regulation of epithelial cell differentiation |
GO_0005856 | Cellular component | cytoskeleton |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005925 | Cellular component | focal adhesion |
GO_0005829 | Cellular component | cytosol |
GO_0005912 | Cellular component | adherens junction |
GO_0005634 | Cellular component | nucleus |
GO_0050473 | Molecular function | arachidonate 15-lipoxygenase activity |
GO_0008289 | Molecular function | lipid binding |
GO_1990136 | Molecular function | linoleate 9S-lipoxygenase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0036403 | Molecular function | arachidonate 8(S)-lipoxygenase activity |
GO_0005509 | Molecular function | calcium ion binding |
GO_0016165 | Molecular function | linoleate 13S-lipoxygenase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | ALOX15B |
Protein name | Arachidonate 15-lipoxygenase type B Polyunsaturated fatty acid lipoxygenase ALOX15B (15-lipoxygenase 2) (15-LOX-2) (Arachidonate 15-lipoxygenase B) (15-LOX-B) (EC 1.13.11.33) (Arachidonate 15-lipoxygenase type II) (Linoleate 13-lipoxygenase 15-LOb) (EC 1.13.11.-) |
Synonyms | |
Description | FUNCTION: [Isoform A]: Non-heme iron-containing dioxygenase that catalyzes the stereo-specific peroxidation of free and esterified polyunsaturated fatty acids (PUFAs) generating a spectrum of bioactive lipid mediators (Probable). It inserts peroxyl groups at C15 of arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate) producing (15S)-hydroperoxyeicosatetraenoate/(15S)-HPETE (Probable). Also peroxidizes linoleate ((9Z,12Z)-octadecadienoate) to 13-hydroperoxyoctadecadienoate/13-HPODE (Probable) . Oxygenates arachidonyl derivatives such as 2-arachidonoylglycerol (2-AG) leading to the production and extracellular release of 15-hydroxyeicosatetraenoyl glycerol (15-HETE-G) that acts as a peroxisome proliferator-activated receptor alpha agonist . Has the ability to efficiently class-switch ALOX5 pro-inflammatory mediators into anti-inflammatory intermediates . Participates in the sequential oxidations of DHA ((4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate) to generate specialized pro-resolving mediators (SPMs) resolvin D5 ((7S,17S)-diHPDHA), which can actively down-regulate the immune response and have anti-aggregation properties with platelets . In addition to free PUFAs hydrolyzed from phospholipids, it directly oxidizes PUFAs esterified to membrane-bound phospholipids . Has no detectable 8S-lipoxygenase activity on arachidonate but reacts with (8S)-HPETE to produce (8S,15S)-diHPETE (Probable). May regulate progression through the cell cycle and cell proliferation . May also regulate cytokine secretion by macrophages and therefore play a role in the immune response . May also regulate macrophage differentiation into proatherogenic foam cells . .; FUNCTION: [Isoform B]: Does not convert arachidonic acid to 15S-hydroperoxyeicosatetraenoic acid/(15S)-HPETE. . |
Accessions | I3L1D5 O15296 ENST00000380173.6 [O15296-4] ENST00000380183.9 [O15296-1] ENST00000573359.1 [O15296-2] ENST00000572022.5 |